In this study, we developed a preclinical mouse model for neonatal diabetes based on the hFicDR371S mutation identified in humans, which disrupts FicD-mediated deAMPylation of BiP, impairing its regulatory function. This evidence concerns the gene HSPA5 and diabetes mellitus.